Adimmune Past Earnings Performance
Past criteria checks 0/6
Adimmune's earnings have been declining at an average annual rate of -27.3%, while the Biotechs industry saw earnings growing at 23.6% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-27.3%
Earnings growth rate
-21.4%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 5.6% |
| Return on equity | -12.9% |
| Net Margin | -38.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues
Aug 13
Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality
Apr 05Is Adimmune (TPE:4142) Using Debt In A Risky Way?
Mar 01Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years
Jan 07Revenue & Expenses Breakdown
How Adimmune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,571 | -608 | 763 | 256 |
| 30 Jun 24 | 1,657 | -608 | 844 | 289 |
| 31 Mar 24 | 1,659 | -575 | 789 | 270 |
| 31 Dec 23 | 1,785 | -640 | 837 | 297 |
| 30 Sep 23 | 1,810 | -165 | 532 | 348 |
| 30 Jun 23 | 1,924 | -9 | 453 | 343 |
| 31 Mar 23 | 2,369 | 277 | 516 | 342 |
| 31 Dec 22 | 2,252 | 291 | 451 | 346 |
| 30 Sep 22 | 2,613 | 525 | 452 | 294 |
| 30 Jun 22 | 2,279 | 267 | 413 | 265 |
| 31 Mar 22 | 1,840 | 58 | 320 | 294 |
| 31 Dec 21 | 1,794 | 43 | 350 | 321 |
| 30 Sep 21 | 1,670 | 989 | 394 | 410 |
| 30 Jun 21 | 1,534 | 988 | 368 | 443 |
| 31 Mar 21 | 1,509 | 1,008 | 346 | 404 |
| 31 Dec 20 | 1,869 | 1,241 | 311 | 338 |
| 30 Sep 20 | 1,675 | -21 | 236 | 252 |
| 30 Jun 20 | 1,564 | -71 | 229 | 223 |
| 31 Mar 20 | 1,607 | -101 | 241 | 225 |
| 31 Dec 19 | 1,300 | -281 | 231 | 236 |
| 30 Sep 19 | 1,079 | -616 | 234 | 224 |
| 30 Jun 19 | 887 | -733 | 242 | 232 |
| 31 Mar 19 | 812 | -637 | 226 | 209 |
| 31 Dec 18 | 822 | -618 | 225 | 206 |
| 30 Sep 18 | 627 | -564 | 217 | 196 |
| 30 Jun 18 | 538 | -670 | 202 | 178 |
| 31 Mar 18 | 558 | -742 | 216 | 220 |
| 31 Dec 17 | 563 | -760 | 222 | 222 |
| 30 Sep 17 | 648 | -670 | 224 | 227 |
| 30 Jun 17 | 576 | -687 | 255 | 225 |
| 31 Mar 17 | 637 | -643 | 248 | 190 |
| 31 Dec 16 | 607 | -595 | 239 | 165 |
| 30 Sep 16 | 437 | -717 | 261 | 175 |
| 30 Jun 16 | 392 | -779 | 238 | 192 |
| 31 Mar 16 | 308 | -767 | 243 | 178 |
| 31 Dec 15 | 291 | -761 | 242 | 205 |
| 30 Sep 15 | 312 | -655 | 206 | 240 |
| 30 Jun 15 | 270 | -714 | 202 | 223 |
| 31 Mar 15 | 503 | -605 | 202 | 238 |
| 31 Dec 14 | 481 | -614 | 204 | 239 |
| 30 Sep 14 | 473 | -569 | 238 | 246 |
| 30 Jun 14 | 532 | -426 | 247 | 246 |
| 31 Mar 14 | 413 | -584 | 217 | 220 |
| 31 Dec 13 | 414 | -600 | 210 | 189 |
Quality Earnings: 4142 is currently unprofitable.
Growing Profit Margin: 4142 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4142 is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare 4142's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4142 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (27.2%).
Return on Equity
High ROE: 4142 has a negative Return on Equity (-12.89%), as it is currently unprofitable.